B
249.09
-2.06 (-0.82%)
| Previous Close | 251.15 |
| Open | 249.29 |
| Volume | 25,575 |
| Avg. Volume (3M) | 245,551 |
| Market Cap | 7,051,065,344 |
| Price / Earnings (Forward) | 28.99 |
| Price / Sales | 3.05 |
| Price / Book | 1.06 |
| 52 Weeks Range | |
| Earnings Date | 5 May 2025 - 9 May 2025 |
| Profit Margin | -85.16% |
| Operating Margin (TTM) | 9.72% |
| Diluted EPS (TTM) | -76.53 |
| Quarterly Revenue Growth (YOY) | -4.20% |
| Quarterly Earnings Growth (YOY) | -83.30% |
| Total Debt/Equity (MRQ) | 20.50% |
| Current Ratio (MRQ) | 5.99 |
| Operating Cash Flow (TTM) | 515.30 M |
| Levered Free Cash Flow (TTM) | 250.23 M |
| Return on Assets (TTM) | 1.55% |
| Return on Equity (TTM) | -27.52% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Bearish |
| Medical Devices (Global) | Mixed | Bearish | |
| Stock | Bio-Rad Laboratories, Inc. | Bullish | Bearish |
AIStockmoo Score
-0.3
| Analyst Consensus | 5.0 |
| Insider Activity | -2.5 |
| Price Volatility | -2.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 0.5 |
| Average | -0.30 |
|
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (56% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (44% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (42% of 2023 sales), Europe (31%), Asia (31%), and other (6%). Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Core |
| % Held by Insiders | 16.14% |
| % Held by Institutions | 93.04% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 409.00 (RBC Capital, 64.20%) | Buy |
| Median | 337.00 (35.29%) | |
| Low | 265.00 (Wells Fargo, 6.39%) | Hold |
| Average | 337.00 (35.29%) | |
| Total | 1 Buy, 1 Hold | |
| Avg. Price @ Call | 284.60 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| RBC Capital | 01 Aug 2025 | 409.00 (64.20%) | Buy | 284.60 |
| Wells Fargo | 01 Aug 2025 | 265.00 (6.39%) | Hold | 284.60 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| ALLISON SCHWARTZ | - | 296.66 | -88 | -26,133 |
| BARRY JAMES | - | 296.66 | -595 | -176,313 |
| COREY COLLEEN | - | 296.66 | -607 | -180,301 |
| ENGELHARDT EVA ANETTE | - | 295.43 | -413 | -122,013 |
| ENLOE COURTNEY C | - | 295.43 | -275 | -81,243 |
| EVRAN SEDAT | - | 295.43 | -277 | -81,834 |
| LAKKARAJU ROOP KALYAN | - | 295.43 | -550 | -162,487 |
| SCHWARTZ NORMAN D | - | 296.66 | -4,612 | -1,370,079 |
| Aggregate Net Quantity | -7,417 | |||
| Aggregate Net Value ($) | -2,200,402 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 296.25 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| SCHWARTZ NORMAN D | Officer | 06 Sep 2025 | Disposed (-) | 1,528 | 295.43 | 451,417 |
| SCHWARTZ NORMAN D | Officer | 06 Sep 2025 | Option execute | 3,455 | - | - |
| ENLOE COURTNEY C | Officer | 06 Sep 2025 | Disposed (-) | 275 | 295.43 | 81,243 |
| ENLOE COURTNEY C | Officer | 06 Sep 2025 | Option execute | 768 | - | - |
| ENGELHARDT EVA ANETTE | Officer | 06 Sep 2025 | Disposed (-) | 413 | 295.43 | 122,013 |
| ENGELHARDT EVA ANETTE | Officer | 06 Sep 2025 | Option execute | 1,152 | - | - |
| ALLISON SCHWARTZ | Director | 06 Sep 2025 | Disposed (-) | 33 | 295.43 | 9,749 |
| ALLISON SCHWARTZ | Director | 06 Sep 2025 | Option execute | 92 | - | - |
| BARRY JAMES | Officer | 06 Sep 2025 | Disposed (-) | 378 | 295.43 | 111,673 |
| BARRY JAMES | Officer | 06 Sep 2025 | Option execute | 1,056 | - | - |
| COREY COLLEEN | Officer | 06 Sep 2025 | Disposed (-) | 209 | 295.43 | 61,745 |
| COREY COLLEEN | Officer | 06 Sep 2025 | Option execute | 576 | - | - |
| LAKKARAJU ROOP KALYAN | Officer | 06 Sep 2025 | Disposed (-) | 550 | 295.43 | 162,487 |
| LAKKARAJU ROOP KALYAN | Officer | 06 Sep 2025 | Option execute | 1,535 | - | - |
| EVRAN SEDAT | Officer | 06 Sep 2025 | Disposed (-) | 277 | 295.43 | 81,834 |
| EVRAN SEDAT | Officer | 06 Sep 2025 | Option execute | 864 | - | - |
| SCHWARTZ NORMAN D | Officer | 01 Sep 2025 | Disposed (-) | 3,084 | 297.88 | 918,662 |
| SCHWARTZ NORMAN D | Officer | 01 Sep 2025 | Option execute | 6,353 | - | - |
| COREY COLLEEN | Officer | 01 Sep 2025 | Disposed (-) | 398 | 297.88 | 118,556 |
| COREY COLLEEN | Officer | 01 Sep 2025 | Option execute | 1,102 | - | - |
| BARRY JAMES | Officer | 01 Sep 2025 | Disposed (-) | 217 | 297.88 | 64,640 |
| BARRY JAMES | Officer | 01 Sep 2025 | Option execute | 602 | - | - |
| ALLISON SCHWARTZ | Director | 01 Sep 2025 | Disposed (-) | 55 | 297.88 | 16,383 |
| ALLISON SCHWARTZ | Director | 01 Sep 2025 | Option execute | 147 | - | - |
| Show more | ||||||
| Date | Type | Details |
|---|---|---|
| 25 Aug 2025 | Announcement | Bio-Rad's Management to Participate in Upcoming Investor Conferences |
| 01 Aug 2025 | Announcement | Bio-Rad to Host Droplet Digital PCR Webinar on Tuesday, August 26, 2025 |
| 31 Jul 2025 | Announcement | Bio-Rad Reports Second-Quarter 2025 Financial Results |
| 28 Jul 2025 | Announcement | Bio-Rad Appoints Rajat Mehta Executive Vice President, Global Commercial Operations |
| 17 Jul 2025 | Announcement | Bio-Rad to Report Second Quarter 2025 Financial Results on Thursday, July 31, 2025 |
| 07 Jul 2025 | Announcement | Bio-Rad Expands Droplet Digital PCR Offering Through Strategic Acquisition and Platform Rollout |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |